Table 1.
Different Characteristics of Peptic Ulcer Bleeding Patients with Helicobacter pylori Eradication within 120 Days and after 120 Days of the Initial Diagnosis
| Variable | Early ≤120 days | Late >120 days | p-value |
|---|---|---|---|
| No. of patients | 1,256 | 664 | |
| Age, yr | 0.065 | ||
| 20–49 | 469 (37.34) | 227 (34.19) | |
| 50–69 | 518 (41.24) | 264 (39.76) | |
| ≥70 | 269 (21.42) | 173 (26.05) | |
| Sex | 0.461 | ||
| Male | 884 (70.38) | 478 (71.99) | |
| Female | 372 (29.62) | 186 (28.01) | |
| Rehospitalization* | <0.001 | ||
| No | 1,153 (91.80) | 573 (86.30) | |
| Complicated† | 103 (8.20) | 91 (13.70) | |
| Comorbidities | |||
| DM | 154 (12.26) | 107 (16.11) | 0.019 |
| CHF | 34 (2.71) | 20 (3.01) | 0.701 |
| CAD | 167 (13.30) | 112 (16.87) | 0.035 |
| COPD | 146 (11.62) | 92 (13.86) | 0.158 |
| Gastroduodenal ulcer history | 74 (5.89) | 56 (8.43) | 0.035 |
| Ulcer position | <0.001 | ||
| Gastric ulcer | 511 (40.68) | 351 (52.86) | |
| Duodenal ulcer | 728 (57.96) | 298 (44.88) | |
| Peptic ulcer‡ | 17 (1.35) | 15 (2.26) | |
| Medication | |||
| PPIs or H2-blockers | 110 (8.76) | 124 (18.67) | <0.001 |
| Aspirin | 67 (5.33) | 31 (4.67) | 0.528 |
| NSAIDs | 184 (14.65) | 145 (21.84) | <0.001 |
| COX-2 specific inhibitors | 46 (3.66) | 39 (5.87) | 0.025 |
| Steroids | 52 (4.14) | 36 (5.42) | 0.202 |
| Clopidogrel | 20 (1.59) | 12 (1.81) | 0.727 |
| Ticlopidine | 9 (0.72) | 6 (0.90) | 0.658 |
| Warfarin | 4 (0.32) | 3 (0.45) | 0.645 |
| Follow-up year | 5.47±3.22 | 3.93±2.83 |
Data are presented as number (%) or mean±SD.
DM, diabetes mellitus; CHF, congestive heart failure; CAD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; PPIs, proton pump inhibitors; H2-blockers, histamine receptor-2 blockers; NSAIDs, nonsteroidal anti-inflammatory drugs; COX-2, cyclooxygenase-2.
*
Rehospitalization for recurrent peptic ulcers;
†
Rehospitalization for complicated recurrent peptic ulcers with hemorrhages and perforations;
‡
Including gastric ulcer and duodenal ulcer.